Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.40 |
| ▸ | TET3 | O43151 | 8/20 | 0.40 |
| ▸ | FBXL19 | Q6PCT2 | 8/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 8/20 | 0.40 |
| ▸ | CXXC4 | Q9H2H0 | 8/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 8/20 | 0.40 |
| ▸ | CXXC5 | Q7LFL8 | 7/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 6/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22174114 | 0.79 | LMNA (0.44) | KMT2ATET3FBXL19KDM2BCXXC4 | |
| SCHEMBL22173938 | 0.78 | KMT2A (0.42) | KMT2ATET3FBXL19KDM2BCXXC4 | |
| SCHEMBL21635325 | 0.77 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3LRRK2 | |
| SCHEMBL2143219 | 0.74 | USP2 (0.43) | — | |
| SCHEMBL24246661 | 0.74 | — | — | |
| SCHEMBL10063346 | 0.73 | NEK2 (0.40) | SLC6A2SLC6A4SLC6A3LRRK2 | |
| SCHEMBL25809394 | 0.71 | TET3 (0.38) | KMT2ATET3FBXL19KDM2BCXXC4 | |
| SCHEMBL22449836 | 0.70 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3LRRK2 | |
| SCHEMBL22259418 | 0.70 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3LRRK2 | |
| SCHEMBL21658756 | 0.69 | USP2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885TET3 666/4885FBXL19 247/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885TET3 666/4885FBXL19 247/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | KMT2A 3580/4885TET3 4521/4885FBXL19 3394/4885 |
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | KMT2A 3580/4885TET3 4521/4885FBXL19 3394/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885TET3 666/4885FBXL19 247/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | KMT2A 3580/4885TET3 4521/4885FBXL19 3394/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885TET3 666/4885FBXL19 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.